2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

653. Multiple Myeloma: Clinical and Epidemiological: Poster III

Program: Poster Abstract Session
Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Transplantation, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Pharmacology, Radiation Therapy, Women’s Health, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Clinical Practice (Health Services and Quality), Clinical Guidelines, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Value, Diseases, Bone Marrow Failure Syndromes, Hemoglobinopathies, Infectious Diseases, Viral, Lymphoid Malignancies, Plasma Cell Disorders, Myeloid Malignancies, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly
PAPER

5736 World trade center-exposed multiple myeloma shows features of an exposure-associated high-risk phenotype

Maria Victoria del Rosal, MD, Yuki Joyama, MD2, Stephanie Tuminello, PhD3, Sundar Jagannath, M.D.4, Samir Parekh, MD5, Emanuela Taioli, MD, PhD6, Santiago Thibaud, MD7
1 Icahn School Of Medicine at Mount Sinai, New York City, New York, United States
2 Icahn School Of Medicine at Mount Sinai, New York City, New York, United States
3 Icahn School Of Medicine at Mount Sinai, New York City, New York, United States
4 Icahn School Of Medicine at Mount Sinai, New York City, New York, United States
5 Icahn School Of Medicine at Mount Sinai, New York City, New York, United States
6 Icahn School Of Medicine at Mount Sinai, New York City, New York, United States
7 Icahn School Of Medicine at Mount Sinai, New York City, New York, United States

Introduction

Multiple myeloma (MM) is recognized as a World Trade Center (WTC)-related malignancy, with prior studies showing increased MM and precursor plasma cell disorder risk among WTC-exposed responders. However, whether WTC-exposed MM has distinct clinical or cytogenetic features remains unknown. This question is clinically relevant because translational studies in other WTC-associated cancers have linked exposure to inflammatory, epigenetic, and molecular features of aggressive disease. We therefore conducted a comprehensive clinical and cytogenetic characterization of WTC-exposed MM compared with non-WTC institutional controls.

Methods

We performed a retrospective single-institution cohort study of WTC-exposed newly-diagnosed MM (NDMM)  patients (n=108) and non-WTC NDMM controls with diagnostic FISH data (n=2,097). WTC exposure was ascertained from clinical documentation and WTC Health Program records. We compared demographic features, age at diagnosis, FISH-defined cytogenetic abnormalities, 2025 IMS/IMWG high-risk disease, additional primary malignancies, and clinical outcomes. Regression models were adjusted for age, sex, and race as appropriate, with Benjamini-Hochberg correction across the main clinical/cytogenetic comparisons. PFS after frontline therapy (PFS1) and OS were evaluated among patients with longitudinal follow-up.

Results

Among 2,205 NDMM patients, WTC-exposed patients were more often male than controls (74.1% vs 53.7%; P<.001), consistent with the sex distribution of the WTC responder population. Racial distribution was similar between groups (P=.801). MM was diagnosed a median of 16.3 years after WTC exposure (range 3.6-24.1 years). WTC-exposed patients were younger at MM diagnosis than controls (mean, 58.3 vs 63.0 years). After adjustment for sex and race, WTC exposure remained associated with diagnosis 4.6 years earlier (95% CI, −6.7 to −2.5; P<.001; FDR q<.001). This association persisted when restricted to the shared age range of both cohorts (adjusted difference, −3.9 years; 95% CI, −5.9 to −2.0; P<.001). High-risk cytogenetics were more frequent in WTC-exposed patients than controls (21.3% vs 14.8%; adjusted OR, 1.65; 95% CI, 1.02-2.67; P=.04; FDR q=.04). 17p deletion/TP53 loss was numerically enriched in WTC-exposed patients (12.0% vs 7.9%), although this association did not reach statistical significance (adjusted OR, 1.71; 95% CI, 0.93–3.16; P=.08). Additional primary malignancies were markedly more common in WTC-exposed patients (31.5% vs 18.7%; adjusted RR, 2.05; 95% CI, 1.53-2.75; P<.001; FDR q<.001), including after exclusion of nonmelanoma skin cancer (26.9% vs 16.5%; adjusted RR, 2.00; 95% CI, 1.44-2.78; P<.001). Among patients with at least one additional primary malignancy, WTC-exposed patients were more likely to have two or more additional primary malignancies than controls (41.2% vs 17.8%; P=.003). Exploratory survival analyses showed no significant difference in adjusted PFS1 or OS.

Conclusions

In the largest WTC-exposed MM cohort characterized to date, WTC-exposed patients were diagnosed at younger age, had higher rates of high-risk cytogenetics at diagnosis, and additional primary malignancies than non-WTC controls. These findings suggest that WTC-exposed MM may represent a clinically relevant exposure-associated phenotype, rather than simply excess MM incidence. For treating clinicians, WTC exposure history may be relevant to risk assessment, review of prior and subsequent malignancies, and future surveillance strategies. Prospective molecular and exposomic studies are needed to validate these findings and define the biology underlying this phenotype.

Maria Victoria del Rosal, MD: No relevant conflicts of interest to declare.